{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:06:24Z","timestamp":1769601984581,"version":"3.49.0"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Advanced gastrointestinal stromal tumors (GIST) are typically treated with tyrosine kinase inhibitors, and imatinib is the most commonly used standard of care in first line treatments. The use of this and other tyrosine kinase inhibitors is associated with objective tumor responses and prolongation of progression-free and overall survival, but the treatment of metastatic disease is non-curative due to the selection or acquisition of secondary mutations and the activation of alternative kinase signaling pathways, leading to resistance and disease progression after an initial response. The present preclinical study evaluated the potential use of the fibroblast growth factor receptor inhibitors infigratinib and dovitinib alone or in combination with the mitogen-activated protein kinase inhibitor binimetinib in mouse models of GIST with different sensitivity or resistance to imatinib. Patient- and cell-line-derived GIST xenografts were established by bilateral, subcutaneous transplantation of human GIST tissue in female adult nu\/nu NMRI mice. The mice were treated with dovitinib, infigratinib, or binimetinib, either alone or in combination with imatinib. The safety of treated animals was assessed by well-being inspection and body weight measurement. Antitumor effects were assessed by caliper-based tumor measurement. H&amp;E staining and immunohistochemistry were used for assessing anti-mitotic and pro-apoptotic activity of the experimental treatments. Western blotting was used for assessing effects of the agents on kinase signaling pathways. Anti-angiogenic activity was assessed by measuring tumor vessel density. Dovitinib was found to have antitumor efficacy in GIST xenografts characterized by different imatinib resistance patterns. Dovitinib had better efficacy than imatinib (both at standard and increased dose) and was found to be well tolerated. Dovitinib had better efficacy in a KIT exon 9 mutant model, highlighting a role of patient selection in clinical GIST trials with the agent. In a model with KIT exon 11 and 17 mutations, dovitinib induced tumor necrosis, most likely due to anti-angiogenic effects. Additive effects combining dovitinib with binimetinib were limited.<\/jats:p>","DOI":"10.3390\/biomedicines10051135","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T09:27:56Z","timestamp":1652520476000},"page":"1135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"first","affiliation":[{"name":"Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium"},{"name":"Research Unit Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yemarshet","family":"Gebreyohannes","sequence":"additional","affiliation":[{"name":"Research Unit Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Van Looy","sequence":"additional","affiliation":[{"name":"Research Unit Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9722-7863","authenticated-orcid":false,"given":"Paul","family":"Manley","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, St. Johann Campus, 4002 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Growney","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, St. Johann Campus, 4002 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Squires","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, Cambridge, MA 02139, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9726-144X","authenticated-orcid":false,"given":"Agnieszka","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Research Unit Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal Stromal Tumors","volume":"36","author":"Joensuu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"de Pinieux, G., Karanian, M., Le Loarer, F., Le Guellec, S., Chabaud, S., Terrier, P., Bouvier, C., Batistella, M., Neuville, A., and Robin, Y.-M. (2021). Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0246958"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","article-title":"Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation","volume":"11","author":"Antonescu","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","article-title":"Molecular correlates of imatinib resistance in gastrointestinal stromal tumors","volume":"24","author":"Heinrich","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1038\/sj.onc.1210173","article-title":"A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors","volume":"26","author":"Mahadevan","year":"2007","journal-title":"Oncogene"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/0008-5472.CAN-14-0573","article-title":"Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance","volume":"75","author":"Traer","year":"2015","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12967-016-1075-6","article-title":"FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors","volume":"14","author":"Shi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1158\/1541-7786.MCR-16-0376","article-title":"Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST","volume":"15","author":"Pantaleo","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Boichuk, S., Galembikova, A., Mikheeva, E., Bikinieva, F., Aukhadieva, A., Dunaev, P., Khalikov, D., Petrov, S., Kurtasanov, R., and Valeeva, E. (2020). Inhibition of FGF2-Mediated Signaling in GIST\u2014Promising Approach for Overcoming Resistance to Imatinib. Cancers, 12.","DOI":"10.3390\/cancers12061674"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","article-title":"FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-19-2035","article-title":"Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors","volume":"26","author":"Facchinetti","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1535-7163.MCT-18-1045","article-title":"Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing","volume":"18","author":"Cornillie","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100832","DOI":"10.1016\/j.tranon.2020.100832","article-title":"Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors","volume":"13","author":"Wang","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-14-1823","article-title":"Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: Rationale and efficacy","volume":"20","author":"Wozniak","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1158\/1535-7163.MCT-16-0224","article-title":"Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations","volume":"15","author":"Gebreyohannes","year":"2016","journal-title":"Mol. Cancer Ther"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2045-3329-4-10","article-title":"Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors","volume":"4","author":"Gebreyohannes","year":"2014","journal-title":"Clin. Sarcoma Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","article-title":"Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate","volume":"12","author":"Wardelmann","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1158\/0008-5472.CAN-14-2564","article-title":"Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors","volume":"75","author":"Cohen","year":"2015","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"abstr 1620","DOI":"10.1158\/1538-7445.AM2013-1620","article-title":"Dovitinib has anti-tumor activity in gastrointestinal stromal tumor (GIST) cell lines","volume":"73","author":"Growney","year":"2013","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-03-0715","article-title":"Gene Expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site","volume":"10","author":"Antonescu","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/bjc.2013.594","article-title":"Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib","volume":"109","author":"Kang","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/bjc.2017.290","article-title":"Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib","volume":"117","author":"Joensuu","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/annonc\/mdu386","article-title":"Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors","volume":"25","author":"Yoo","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1038\/sj.onc.1210558","article-title":"KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase\/AKT is a crucial survival pathway","volume":"26","author":"Bauer","year":"2007","journal-title":"Oncogene"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1309-e983","DOI":"10.1634\/theoncologist.2019-0418","article-title":"A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor","volume":"24","author":"Rosenbaum","year":"2019","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/bjc.2016.263","article-title":"MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model","volume":"115","author":"Mao","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molonc.2012.09.002","article-title":"MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib","volume":"7","author":"Huang","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/CAD.0000000000000637","article-title":"Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors","volume":"29","author":"Boichuk","year":"2018","journal-title":"Anti-Cancer Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10637-018-0648-z","article-title":"A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor","volume":"37","author":"Kelly","year":"2019","journal-title":"Investig. New Drugs"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/5\/1135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:10:38Z","timestamp":1760137838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/5\/1135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["biomedicines10051135"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10051135","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}